Host Defense Peptides from Asian Frogs as Potential Clinical Therapies

Host defense peptides (HDPs) are currently major focal points of medical research as infectious microbes are gaining resistance to existing drugs. They are effective against multi-drug resistant pathogens due to their unique primary target, biological membranes, and their peculiar mode of action. Ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Vineeth T.V., Holthausen, David, Jacob, Joshy, George, Sanil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790330/
https://www.ncbi.nlm.nih.gov/pubmed/27025618
http://dx.doi.org/10.3390/antibiotics4020136
_version_ 1782420975155937280
author Kumar, Vineeth T.V.
Holthausen, David
Jacob, Joshy
George, Sanil
author_facet Kumar, Vineeth T.V.
Holthausen, David
Jacob, Joshy
George, Sanil
author_sort Kumar, Vineeth T.V.
collection PubMed
description Host defense peptides (HDPs) are currently major focal points of medical research as infectious microbes are gaining resistance to existing drugs. They are effective against multi-drug resistant pathogens due to their unique primary target, biological membranes, and their peculiar mode of action. Even though HDPs from 60 Asian frog species belonging to 15 genera have been characterized, research into these peptides is at a very early stage. The purpose of this review is to showcase the status of peptide research in Asia. Here we provide a summary of HDPs from Asian frogs.
format Online
Article
Text
id pubmed-4790330
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47903302016-03-24 Host Defense Peptides from Asian Frogs as Potential Clinical Therapies Kumar, Vineeth T.V. Holthausen, David Jacob, Joshy George, Sanil Antibiotics (Basel) Review Host defense peptides (HDPs) are currently major focal points of medical research as infectious microbes are gaining resistance to existing drugs. They are effective against multi-drug resistant pathogens due to their unique primary target, biological membranes, and their peculiar mode of action. Even though HDPs from 60 Asian frog species belonging to 15 genera have been characterized, research into these peptides is at a very early stage. The purpose of this review is to showcase the status of peptide research in Asia. Here we provide a summary of HDPs from Asian frogs. MDPI 2015-03-30 /pmc/articles/PMC4790330/ /pubmed/27025618 http://dx.doi.org/10.3390/antibiotics4020136 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kumar, Vineeth T.V.
Holthausen, David
Jacob, Joshy
George, Sanil
Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title_full Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title_fullStr Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title_full_unstemmed Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title_short Host Defense Peptides from Asian Frogs as Potential Clinical Therapies
title_sort host defense peptides from asian frogs as potential clinical therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790330/
https://www.ncbi.nlm.nih.gov/pubmed/27025618
http://dx.doi.org/10.3390/antibiotics4020136
work_keys_str_mv AT kumarvineethtv hostdefensepeptidesfromasianfrogsaspotentialclinicaltherapies
AT holthausendavid hostdefensepeptidesfromasianfrogsaspotentialclinicaltherapies
AT jacobjoshy hostdefensepeptidesfromasianfrogsaspotentialclinicaltherapies
AT georgesanil hostdefensepeptidesfromasianfrogsaspotentialclinicaltherapies

Ejemplares similares